EZH2 Y641 Hotspot aktivierende Mutationen treten in ~20-25% des follikulären Lymphoms (und...
Deterministische Ansicht der Quelle YAML Entität. Klinische Autorität bleibt mit den zitierten Quell-IDs und Rezensenten Sign-off Zustand.
| ID | BMA-EZH2-Y641-FL |
|---|---|
| Art | Therapeutische Relevanz |
| Status | reviewed 2026-04-27 | pending_clinical_signoff | actionability review required |
| Erkrankungen | DIS-FL |
| Quellen | SRC-CIVIC SRC-ESMO-FL-2024 SRC-NCCN-BCELL-2025 |
Fakten zur Handlungsfähigkeit
| Biomarker | BIO-EZH2-Y641 |
|---|---|
| Variante | Y641N/F/H/S/C-Aktivierung von Mutationen im SET-Bereich — Hypermethylierung des H3K27-Gain-of-Funktion; ~20-25% des follikulären Lymphoms |
| Erkrankung | DIS-FL |
| ESCAT-Stufe | IB |
| Empfohlene Kombinationen | tazemetostat monotherapy (R/R EZH2-mutated FL after ≥2 prior systemic therapies per SRC-NCCN-BCELL-2025, SRC-ESMO-FL-2024) |
| Zusammenfassung der Beweise | EZH2 Y641 hotspot activating mutations occur in ~20-25% of follicular lymphoma (and rarely in DLBCL/HGBL). Tazemetostat is a selective EZH2 inhibitor FDA-approved for relapsed/refractory FL: in EZH2- mutated FL after ≥2 prior lines, ORR 69%, mPFS 13.8 mo (E7438-202 Morschhauser Lancet Oncol 2020); in EZH2-WT FL, ORR 35%, mPFS 11.1 mo — mutated population had stronger responses, leading to a companion-diagnostic-paired indication per SRC-NCCN-BCELL-2025, SRC-ESMO-FL-2024. |
Anmerkungen
ESCAT IB / OncoKB Level 1. cobas EZH2 Mutation Test is the companion diagnostic. EZH2-WT subset has FDA approval as well but with ~halved ORR — mutation testing improves selection per ESMO 2024. EZH2-Y641 in DLBCL: investigational; not approved (DLBCL trials in combination with R-CHOP have not yet read out positively per SRC-NCCN-BCELL-2025). Source-gap: SRC-E7438-202 (Morschhauser 2020) not yet ingested.
Verwendet von
Keine Rückverweise im YAML-Korpus gefunden.